Ben M. Brumpton, PhD et al P CSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipoprotein) cholesterol (LDL-C) by increasing uptake in the liver. 1 Although some long-term trials have evaluated their safety, broad investigations of outcomes over the lifetime, leveraging genetic variation in serum PCSK9, have seldomly been conducted. We investigated effects of these variants on a range of outcomes to explore unanticipated effects of long-term PCSK9 inhibition.
We linked genotype and phenotype data from 69 422 participants in the population-based HUNT (Nord-Trøndelag Health Study) with hospital records. Coronary heart disease, myocardial infarction, heart failure, venous thrombosis, diabetes mellitus, asthma, chronic obstructive pulmonary disease, allergic rhinitis, and mood disorders were indicated by International Classification of Diseases-Ninth or Tenth Revision codes recorded between September 1987 and March 2016 or selfreport in HUNT2 (1995) (1996) (1997) or HUNT3 (2006 HUNT3 ( -2008 . Using self-report in HUNT, we assessed anxiety, depression, musculoskeletal pain, headaches, pain or stiffness in muscles or joints in at least 3 consecutive months during the last year, gastrointestinal pain, pain in either leg while walking, and pain in the legs while at rest.
Blood pressure, height, weight, and lung function were measured in HUNT by trained nurses or technicians. Nonfasting serum levels of total cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, glucose, and C-reactive protein were measured, and LDL-C was calculated. All-cause mortality was updated from the National Population Registry.
Serum concentrations of PCSK9 were measured in a subsample by ELISA with antibodies obtained from R&D Systems (Minneapolis, MN) as described elsewhere. 2 Because of the sensitive nature of the data, requests to access the dataset from qualified researchers may be sent to HUNT (www.ntnu.edu/hunt). The regional committee for ethics in medical research approved the study, and participants gave informed consent.
We performed a genome-wide association study of serum PCSK9 in 3697 adults using BOLT-LMM adjusted for sex, age, genotyping batch, and 4 principal components. Serum PCSK9 measurements were rank-transformed to normality. The replication cohort included 5304 adults from the TwinGene Study recruited between 2004 and 2008. 3 We defined a new genetic risk score for serum PCSK9 and regressed this and an existing score (rs11206510, rs2479409, rs2149041, rs2479394, rs10888897, rs7552841, and rs562556) on a range of outcomes. 1 For comparision, we used LDL-C-associated variants on HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase; rs12916, rs17238484, rs5909, rs2303152, rs10066707, and rs2006760)-the target of statins. 1 The associations of PCSK9 and HMGCR genetic risk scores with outcomes in HUNT were assessed using linear regression for continuous and logistic regression for binary outcomes, adjusted for age and sex. We performed 2-sample A, The association between PCSK9 and HMGCR genetic risk scores and a range of continuous traits (left) and diseases or traits (right) in the HUNT, scaled to a genetic risk score-determined 0.259 mmol/L (10 mg/dL) decrease in LDL (low-density lipoprotein) cholesterol. The PCSK9 genetic risk score is defined from the discovery genome-wide association study in this study. The existing PCSK9 score and HMGCR score are defined and weighted using results for LDL cholesterolassociated variants from the Global Lipids Genetics Consortium. B, The association between genetically determined serum PCSK9 and a range of continuous traits (amygdala volume, birth weight, body fat, body mass index, caudate volume, chronotype, depressive symptoms, father's age at death, HDL [high-density lipoprotein] cholesterol, hip circumference, hippocampus volume, intracranial volume, LDL cholesterol, mean platelet volume, mother's age at death, neuroticism, nucleus accumbens volume, pallidum volume, parents' age at death, platelet count, putamen volume, sitting height ratio, sleep duration, thalamus volume, top 1% survival, total cholesterol, triglycerides, waist circumference, waist-to-hip ratio, and years of schooling; left) and diseases or traits (alcohol dependence, Alzheimer disease, amyotrophic lateral sclerosis, autism, bulimia nervosa, coronary heart disease, Crohn disease, eczema, inflammatory bowel disease, lung adenocarcinoma, lung cancer, multiple sclerosis, myocardial infarction, rheumatoid arthritis, schizophrenia, squamous cell lung cancer, type 2 diabetes mellitus, and ulcerative colitis; right) in MR-Base. The new PCSK9 genetic risk score had an r 2 and F statistics of 2.1% and 80.55 for serum PCSK9. BMI indicates body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HADS, Hospital Anxiety and Depression Scale; and OR, odds ratio.
Mendelian randomization on 48 outcomes using large biobanks available in MR-Base. 4 We assessed 11.67 million single-nucleotide and indel variants imputed from a combined reference panel, including 2202 low-pass sequenced HUNT genomes and the Haplotype Reference Consortium panel. We identified genome-wide significant associations at 2 loci-PCSK9 and PCSK2. Three independent genome-wide significant variants were identified; the most strongly associated variant was rs11591147 in PCSK9 (p.R46L), which was associated with a 1.30-unit decrease in rank-transformed serum PCSK9 (P=2.9×10 −31 ) per effect allele (SD of original PCSK9 measurements, 47.5 ng/mL; interquartile range, 100.6-154.9), followed by the intronic rs499883 in PCSK9 (β=0.19; P=2.3×10 −15 ) and rs192265866 in PCSK2 (β=−1.05; P=2.8×10 −8 ) of which the 2 variants in PCSK9 (but not the variant in PCSK2) replicated in TwinGene and were used to construct a new genetic risk score for PCSK9.
Our results demonstrated probable causal associations between lower serum PCSK9 and both lower serum LDL-C (P=2.8×10 −43 ) and lower risk of coronary heart disease (P=8.9×10 −4 ; Figure [A] ). Because analyses within HUNT suggested associations between PCSK9 and HMGCR genetic risk scores and risk of venous thrombosis and asthma, respectively, we investigated associations using summary-level data from the INVENT (International Network against Thrombosis) Consortium and GABRIEL (A Multidisciplinary Study to Identify the Genetic and Environmental Causes of Asthma in the European Community). 4, 5 Neither associations replicated (venous thrombosis, inverse-variance weighted: odds ratio [OR], 1.38; 95% confidence interval [CI], 0.88-2.20; asthma, inverse-variance weighted: OR, 1.13; 95% CI, 0.64-1.98). We did not observe any other convincing associations across a range of cardiovascular, respiratory, mental, diabetes mellitus, or painrelated outcomes.
Utilizing genome-wide association study summary statistics and 2-sample MR, the PCSK9 genetic risk score was associated with LDL-C, HDL cholesterol, and total cholesterol as expected (Figure [B] ). Moreover, genetically decreased serum PCSK9 was associated with higher father's age at death (β=0.04; 95% CI, 0.01-0.08), parents age at death (β=0.05; 95% CI, 0.01-0.10), and waist-to-hip ratio (β=0.03; 95% CI, 0.01-0.06; Figure  [B] ). Additionally, genetically decreased serum PCSK9 was associated with decreased risk of coronary heart disease (OR, 0.84; 95% CI, 0.78-0.89) and myocardial infarction (OR, 0.81; 95% CI, 0.70-0.93) and an increased risk of Alzheimer disease (OR, 1.27; 95% CI, 1.04-1.55; Figure [B] ).
In summary, we confirmed 2 independent genetic variants associated with serum PCSK9 and causal associations of lower serum PCSK9 with lower LDL-C and reduced risk of coronary heart disease. Additionally, we did not observe any other consistent unexpected associations when investigating a range of outcomes. The lack of association with a range of potential adverse outcomes is reassuring for long-term use of PCSK9 inhibitors.
